Last kr92.75 SEK
Change Today +8.25 / 9.76%
Volume 925.6K
MVIRB On Other Exchanges
Symbol
Exchange
Stockholm
OTC US
OTC US
Frankfurt
Stockholm
As of 11:29 AM 02/27/15 All times are local (Market data is delayed by at least 15 minutes).

medivir ab-b shs (MVIRB) Snapshot

Open
kr89.75
Previous Close
kr84.50
Day High
kr95.75
Day Low
kr89.50
52 Week High
06/12/14 - kr140.93
52 Week Low
01/23/15 - kr80.03
Market Cap
2.5B
Average Volume 10 Days
374.8K
EPS TTM
kr33.82
Shares Outstanding
26.2M
EX-Date
--
P/E TM
2.7x
Dividend
--
Dividend Yield
--
Current Stock Chart for MEDIVIR AB-B SHS (MVIRB)

Related News

No related news articles were found.

medivir ab-b shs (MVIRB) Related Businessweek News

No Related Businessweek News Found

medivir ab-b shs (MVIRB) Details

Medivir AB, a research-based specialty pharmaceutical company, develops and markets pharmaceuticals for the treatment of infectious diseases in the Nordic region. It focuses on the research and development of antiviral pharmaceuticals primarily in the hepatitis C area; and other areas, such as bone-related disorders and neuropathic pain. The company also supplies prescription pharmaceuticals, including 16 prescription pharmaceuticals in different therapeutic areas, including Mollipect, Teovent, and Theo-Dur in respiratory organs; Probecid for gout; Nitroglycerin BioPhausia, Digoxin BioPhausia, and Suscard for cardiovascular system; simeprevir for liver disease; Laxabon and Egazil for gastrointestinal system; Xerclear for cold sores; Lithionit and Adasuve for psychiatry; Paraflex for the musculoskeletal system; Citodon and Morfin Special for pain; and Solvezink for zinc deficiency. Medivir AB is headquartered in Stockholm, Sweden.

137 Employees
Last Reported Date: 11/20/14

medivir ab-b shs (MVIRB) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

medivir ab-b shs (MVIRB) Key Developments

Medivir AB Announces Board Changes

Medivir AB announced the Nomination Committee's proposal for a new Board of Directors that will be submitted to the 2015 Annual General Meeting. The 2014-2015 Nomination Committee comprises representatives of the company's three large shareholders at the end of the third quarter of 2014 who have accepted a seat on the Nomination Committee, and the Chairman of the Board. The composition of the 2014-2015 Nomination Committee was as follows: Anders Algotsson, Chairman of the Nomination Committee, representing AFA Försäkring; Maria Rengefors, representing Nordea Fonder; Birgitta Stymne Göransson, Chairman of the Board of Medivir AB; and Bo Öberg, representing the class A shareholders. The new election of two Members, namely Johan Harmenberg and Helena Levander. Björn C. Andersson has declined re-election and Niklas Prager resigned his seat on the Board in September 2014 in conjunction with his appointment as President & CEO of the company.

Medivir AB Announces Executive Changes

Medivir AB announced a reorganization of the management team in order to streamline and increase operational focus. After the change the company´s management team consists of 6 people, including the CEO, vs. previously 8 people. Two new functions are created: Strategic Business Development, which is a consolidation of Corporate Development and Business Development, and Finance & Administration, which is a consolidation of the current Finance & Administration function and Corporate Affairs & IR. The management team will be strengthened with two new colleagues with long experience from strategic business development as well as finance. Christine Lind has been recruited as new head of Strategic Business Development. New CFO, with responsibility also for IR, will be Ola Burmark. Christina Kassberg, Rein Piir, Paul Wallace and Håkan Wallin have chosen to leave the company by the end of February. The new organization will be effective on March 1, 2015.

Medivir AB Announces Sales Results for the Fourth Quarter of 2014

Medivir AB announced sales results for the fourth quarter of 2014. For the quarter, net sales of OLYSIO (simeprevir) amounted to $321 million, of which $256 million were sales in the USA.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MVIRB:SS kr92.75 SEK +8.25

MVIRB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for MVIRB.
View Industry Companies
 

Industry Analysis

MVIRB

Industry Average

Valuation MVIRB Industry Range
Price/Earnings 2.3x
Price/Sales 1.5x
Price/Book 1.2x
Price/Cash Flow 2.2x
TEV/Sales 0.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MEDIVIR AB-B SHS, please visit www.medivir.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.